Ethical issues competence

This high attrition rate, particularly during late preclinical and clinical development, carries a large price tag for the pharmaceutical and biotechnology industry, which is carried over to health care providers. In addition, compounds which qualify for clinical use but fail due to safety matters raise serious ethical issues and questions concerning the responsibility and competence of the industry and registration authorities. 

In most cases, the competent ethics committee for clinical tried approved is a central one. Until the new Decree of the Minister of Hecdth on clinical trials is issued, regional ethics committees are responsible for certain humcin phase III trials. This situation may be changed by the Decree. Updated NIP guidelines or information clarifying the recent situation are always available in English. 

According to Royal Decree 561/93 (article 41), on the minimum requirements for the accreditation of an ethics commitee of clinical research, it is stated that at least one hospital pharmacist must belong necessarily to the commitee. In this way, clinical pharmacists are capable of evaluating methodological and logistical aspects of each protocol and are competent to consider the ethical issues of clinical trials. 

Within a period of perhaps 15 or 20 years, we have witnessed a profound maturation within the profession of pharmacy. The utterances of the profession, as projected in its hterature, have evolved from mostly self-centered and self-serving issues of trade protection to a composite of expressed professional interests that prominently include responsible explorations of scientiflc/technological questions and ethical issues that promote the best interests of the chentele served by the profession. With the pubhcation of Pharmacotherapy A Pathophysiologic Approach, pharmacy s utterances bespeak a matured practitioner who is able to caU upon unique knowledge and skills so as to function as an appropriately confident, independently competent pharmacotherapeutics expert. 

The sponsor may not start a clinical trial until the Ethics Committee has issued a favourable opinion and inasmuch as the competent authority of the Member State concerned has not informed the sponsor of any grounds for non-acceptance. The procedures to reach these decisions can be run in parallel or not, depending on the sponsor. 

All CTs (phase IV ones included) need ethical approval by independent central or regional ethics committees, as specified by a Decree of the Minister of Health in 1987, to be issued in an amended form in 1999. Phase I-III trials also need authorization by the competent medicine regulatory authority (the NIP or the Executive Office of the National Chief Medical Officer). The documentation needed for authorization does not differ from that in the EU. In short, it consists of the following (if not specified, it may be in English German may also be accepted) ... 

In performing its activities, the companies shall not damage the image of competing companies or their products. The companies, which must issue specific internal directives for their staff, shall also be ethically and professionally responsible for the behaviour of their staff when engaged on corporate business. 

This book is designed to provide an overview of the medication issues and concerns that social workers will encounter in practice. The philosophy of the authors is simple We believe that the knowledge and use of medications in the field of social work is necessary for ethical and competent social work practice. To assist the social worker in providing health and mental services, special emphasis is placed on the role of the social worker with regard to new trends in the field and the knowledge of medication use and misuse. 

Ethical considerations must be applied from the design to the completion of a clinical trial. Clear scientific hypotheses and objectives are critical. It is difficult to justify a clinical study if it is not clinically important or relevant. There are added ethical considerations for cancer patients, many of whom have been heavily pretreated with other chemotherapy agents and many of whom are terminally ill and may not derive any direct benefit from the agent being studied, particularly in phase 0 and I trials [23]. Clinical trials are conducted under guidelines issued in the Belmont Report of 1978 that protects human subjects and follows principles of respect for persons, beneficence, and justice. Scientific conduct is also guided by ethical principles in that competent and rigorous analysis is required to prevent compromise of the results [24]. 

Students Need for Better Ethics Competency. One gap analysis theme accumulates around the issues of the legal and ethical competencies of mechanical engineering education. Students reported the need for more training in reliability (40%), safety (37%), leadership (32%), conflict resolutions (26%), business ethics (24%), and legal information (22%). 

It is important to prepare students to deal with the broad field of socio-scientific issues related to the curriculum of chemistry classes (Fensham, 2004 Zeidler, 2003). Also of importance here is to qualify chemistry teachers for the challenge, so they are able to integrate socio-scientific issues in their daily work. Since ethical or philosophical reflections are not part of the curriculum of the science teacher education, it will be difficult to incorporate socio-scientific issues into science classes. Because of the differences between humanities and sciences (see Snow, 1959), science teachers feel insecure about their abiUties to teach outside their discipline in order to foster ethical decision-making competence without the necessary qualifications (see Bauer, 1990 Hofstein, Eilks, Bybee, 2010). 

---